Insomnia Drugs Market by Type, Distribution Channels

List of Tables

The Insomnia Drugs Market is projected to reach USD 4.30 billion by 2030 from USD 2.79 billion in 2022, at a CAGR of 5.56% during the forecast period.

Global Insomnia Drugs Market

KEY MARKET STATISTICS
Base Year Value [2022]	USD 2.79 billion
Estimated Year Value [2023]	USD 2.92 billion
Forecast Year Value [2030]	USD 4.30 billion
CAGR (%)	5.56%

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Insomnia Drugs Market.

Based on Type, market is studied across Anti-Parkinsonian Drugs, Anticonvulsants, Antidepressants, Antinarcoleptics, Benzodiazepines, Nonbenzodiazepines, Orexin Antagonist, and Ramelteon. The Antinarcoleptics is projected to witness significant market share during forecast period.

Based on Distribution Channels, market is studied across Online Pharmacies and Retail Pharmacies. The Retail Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Asia-Pacific is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Insomnia Drugs Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Insomnia Drugs Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Insomnia Drugs Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, Astellas Pharma Inc., Aurobindo Pharma Limited, Biogen SA, Cadila Healthcare Ltd., Dr.Reddy's Laboratories Limited, Eisai Co., Ltd., Eli Lilly and Company, Flynn Pharma Limited, Glenmark Pharmaceuticals Ltd., Idorsia Pharmaceuticals Ltd., LA Herbal (India), Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Minerva Neurosciences, Inc., Neuracle Lifesciences Private Limited, Neurim Pharmaceuticals LTD., Orexo AB, Pfizer Inc., Purdue Pharma L.P., Sanofi Group, Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Vanda Pharmaceuticals Inc., and Wockhardt Limited.

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Insomnia Drugs Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Insomnia Drugs Market?

3. What is the competitive strategic window for identifying opportunities in the Insomnia Drugs Market?

4. What are the latest technology trends and regulatory frameworks in the Insomnia Drugs Market?

5. What is the market share of the leading vendors in the Insomnia Drugs Market?

6. Which modes and strategic moves are suitable for entering the Insomnia Drugs Market?

Product Code: MRR-F6513A06BEC1

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Insomnia Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of insomnia across the world
  - 5.1.1.2. Rising awareness about various treatment options available for insomnia
- 5.1.2. Restraints
  - 5.1.2.1. Side effects associated with insomnia drugs
- 5.1.3. Opportunities
  - 5.1.3.1. Continuous research and development to develop novel insomnia drugs
  - 5.1.3.2. Increase in number of insomnia centers and sleep diagnostic centers
- 5.1.4. Challenges
  - 5.1.4.1. Misconceptions about the seriousness of insomnia and patients' non-adherence to the treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Insomnia Drugs Market, by Type

6.1. Introduction
6.2. Anti-Parkinsonian Drugs
6.3. Anticonvulsants
6.4. Antidepressants
6.5. Antinarcoleptics
6.6. Benzodiazepines
6.7. Nonbenzodiazepines
6.8. Orexin Antagonist
6.9. Ramelteon

7. Insomnia Drugs Market, by Distribution Channels

7.1. Introduction
7.2. Online Pharmacies
7.3. Retail Pharmacies

8. Americas Insomnia Drugs Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Insomnia Drugs Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Insomnia Drugs Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

12.1. Key Company Profiles
- 12.1.1. Alembic Pharmaceuticals Limited
- 12.1.2. Astellas Pharma Inc.
- 12.1.3. Aurobindo Pharma Limited
- 12.1.4. Biogen SA
- 12.1.5. Cadila Healthcare Ltd.
- 12.1.6. Dr.Reddy's Laboratories Limited
- 12.1.7. Eisai Co., Ltd.
- 12.1.8. Eli Lilly and Company
- 12.1.9. Flynn Pharma Limited
- 12.1.10. Glenmark Pharmaceuticals Ltd.
- 12.1.11. Idorsia Pharmaceuticals Ltd.
- 12.1.12. LA Herbal (India)
- 12.1.13. Mallinckrodt Pharmaceuticals
- 12.1.14. Merck & Co., Inc.
- 12.1.15. Minerva Neurosciences, Inc.
- 12.1.16. Neuracle Lifesciences Private Limited
- 12.1.17. Neurim Pharmaceuticals LTD.
- 12.1.18. Orexo AB
- 12.1.19. Pfizer Inc.
- 12.1.20. Purdue Pharma L.P.
- 12.1.21. Sanofi Group
- 12.1.22. Sun Pharmaceutical Industries Limited
- 12.1.23. Takeda Pharmaceutical Company Limited
- 12.1.24. Vanda Pharmaceuticals Inc.
- 12.1.25. Wockhardt Limited
12.2. Key Product Portfolio

13. Appendix

13.1. Discussion Guide
13.2. License & Pricing